[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"melanoma-advanced\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:melanoma-advanced":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,40],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100627160","phase-4-rws-of-tunlametinib-in-nras-mutant-advanced-melanoma-100627160",false,"NCT07445022","RWS of Tunlametinib in NRAS-Mutant Advanced Melanoma","A Prospective, Open-Label, Multicenter, Real-World Study to Evaluate the Efficacy and Safety of Tunlametinib in Patients With NRAS-Mutant Advanced Melanoma","Inclusion Criteria:\n\n* Aged ≥18 years (inclusive), male or female;\n* Patients with histologically or cytologically confirmed locally advanced or metastatic melanoma;\n* Prior genetic testing results showing positive NRAS mutation;\n* Patients who have failed prior anti-PD-1\u002FPD-L1 therapy;\n* Able to take oral medications;\n* Voluntarily participate and sign the informed consent form, expected to have good compliance, and able to cooperate with the study according to the protocol requirements.\n\nExclusion Criteria:\n\n* Currently participating in other clinical trials of drugs;\n* Patients who are pregnant or breastfeeding;\n* Other conditions deemed unsuitable for targeted therapy after multidisciplinary discussion;\n* Other conditions considered inappropriate for inclusion by the investigator, such as familial or social factors that may affect the safety of the subject or the collection of data.","ALL","18 Years",{"count":19,"type":20},110,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","This study is a prospective, open-label, multicenter, real-world clinical study to evaluate the efficacy and safety of tunlametinib in patients with NRAS-mutant advanced melanoma who have failed prior anti-PD-1\u002FPD-L1 therapy.",[26],"Melanoma Advanced","RECRUITING","2026-02-25",{"date":30,"type":31},"2026-03-03","ACTUAL",{"date":33,"type":31},"2026-01-28",{"date":35,"type":20},"2029-01-31",{"name":37,"class":38},"Fudan University","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":51,"conditions":52,"keywords":56,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":71},"100576398","observational-study-of-patients-with-advanced-melanoma-skin-cancer-to-assess-if-iopener-melanoma-test-can-predict-response-to-immunotherapy-100576398","NCT06784778","Observational Study of Patients With Advanced Melanoma (Skin Cancer) to Assess if IOpener®-Melanoma Test Can Predict Response to Immunotherapy.","A Prospective, Observational, Multicenter Clinical Performance Study to Evaluate IOpener®-Melanoma Test for Predicting Response to Combination or Mono Immunotherapy in Stage III or IV Cutaneous Melanoma Patients.","COMO","Inclusion Criteria:\n\n* First line treatment for unresectable stage III or IV cutaneous melanoma (according to AJCC version 8) with anti-PD1 monotherapy (nivolumab or pembrolizumab) or anti-PD1 + anti-CTL4A combination therapy (nivolumab and ipilimumab).\n* Anticipated life expectancy exceeding 3 months.\n* Aged 18 years or older and able to provide written informed consent.\n\nPatients who have completed adjuvant treatment with anti-PD1 immunotherapy at least 6 months ago can be included.\n\nExclusion Criteria:\n\n* Prior treatment for irresectable stage III or stage IV melanoma with BRAF\u002FMEK inhibitors.\n* Presence of progressive\u002Fsymptomatic brain metastases at baseline.\n* WHO performance score ≥ 2.\n* Adjuvant treatment with anti-PD1 immunotherapy received within the last 6 months.\n* Patients undergoing experimental treatments or therapies.\n* Presence of any medical or other condition that in the opinion of the investigator(s) would preclude the participation in a clinical study.\n* Unwillingness or inability to comply with study and follow-up procedures.",{"count":49,"type":20},196,"OBSERVATIONAL","The goal of this observational study is to assess whether the IOpener® melanoma test can assist treating physicians in deciding which therapy is most suitable for patients with skin cancer (advanced cutaneous melanoma). For this purpose it is evaluated how well the IOpener-melanoma test can predict the result of cancer treatment in the treatment groups (standard of care anti-PD1 mono-therapy and standard of care anti-PD1 + anti-CTLA-4 therapy).\n\nParticipants will be asked to provide blood sample for analysis using IOpener®-melanoma test. Patients will receive regular medical care, the test results will not be used to make any treatment decisions. The patients will visit the clinic for treatment administration and clinical evaluation as part of their regular medical care.",[53,54,55,26],"Melanoma Metastatic","Melanoma, Skin","Melanoma Stage III or IV",[57,58,59,60],"melanoma","IOpener","immunotherapy","immune checkpoint inhibitor","2025-02-25",{"date":63,"type":31},"2025-02-28",{"date":65,"type":31},"2024-07-12",{"date":67,"type":20},"2027-07",{"name":69,"class":70},"Pamgene International B.V.","INDUSTRY",3]